If you've already registered, please click here to log in to the webcast
Failure due to safety reasons is the leading cause of drug candidate attrition during discovery and development. Halting the progress of a flawed treatment in the embryonic discovery phase avoids harming humans later down the line and can save organizations valuable time and tens of millions of dollars.
Target Safety Assessments (TSAs) can help organizations to identify and assess unintended adverse consequences of potential treatments, before expensive investment is made. This enables companies to mitigate against target-related toxicities, or to prioritize targets with lower safety risks across the early drug discovery portfolio.
This webcast will discuss the changing landscape of Target Safety Assessment, including how R&D teams are increasingly using Augmented Intelligence techniques to deliver comprehensive, evidence-based TSAs that improve their understanding of biological target safety and ultimately deliver safer patient outcomes.
Webcast attendees will: